Research programme: topoisomerase I inhibitors - Reata Pharmaceuticals

Drug Profile

Research programme: topoisomerase I inhibitors - Reata Pharmaceuticals

Alternative Names: HKH 40A; RTA 501; RTA 502

Latest Information Update: 12 Oct 2015

Price : $50

At a glance

  • Originator National Cancer Institute (USA)
  • Developer Reata Pharmaceuticals
  • Class Acridines; Naphthalimides
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 04 Feb 2011 No development reported - Preclinical for Cancer in USA (unspecified route)
  • 06 Dec 2006 Data presented at the 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2006) added to the Cancer pharmacodynamics section
  • 19 Apr 2006 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top